Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

• Status: Completed
• Trial end date: 2018-02-07
• Target enrollment: 0
• Participant gender: All

Summary

This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Medical history of Heart Failure (HF) with at least 1 prior hospitalization for HF or clinical evidence of HF (without hospitalization) manifested by signs or symptoms of volume overload or elevated intracardiac pressures (e.g., elevated jugular venous pressure, shortness of breath or signs of pulmonary congestion on x-ray or auscultation, peripheral edema) that required/requires treatment with a diuretic for improvement,

• Evidence of cardiac involvement by echocardiography with an end-diastolic interventricular septal wall thickness > 12 mm,

• Presence of amyloid deposits in biopsy tissue and presence of a variant TTR genotype and/or TTR precursor protein identification by immunohistochemistry, scintigraphy or mass spectrometry

Exclusion Criteria:

• A New York Heart Association (NYHA) classification of IV.

• Presence of primary (light chain) amyloidosis.

• Prior liver or heart transplantation or implanted cardiac mechanical assist device.